Vical Incorporated (VICL)
Oncology Corporate Profile
- Products & Overview
- Recent News
HQ Location
10390 Pacific Center CourtSan Diego, CA 92121
Company Description
Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It develops DNA-based vaccines and therapeutics for the prevention/treatment of infectious diseases, cardiovascular diseases, and cancer, including Allovectin-7 cancer immunotherapeutic, a Phase III clinical trial product for the treatment of metastatic melanoma.
Website: http://www.vical.com/
Commercial Products
This company does not have any commercial productsPipeline Products
- Brand
- Generic
- Investigational
| Brand / Product | Class | Area of Study | Phase | Partnership |
|---|---|---|---|---|
| Allovectin-7® | immunotherapy | 1st line metastatic Melanoma | III | |
| IL-2/EP | immunotherapy | Metastatic Melanoma | I |
View additional information on product candidates here »
Recent News Headlines
(TradingMarkets) August 26, 2010 - GlaxoSmithKline, or GSK, has confirmed that the European Commission has granted marketing authorization to amend the license for its cervical cancer vaccine, Cervarix.
(Marketwatch) August 24, 2010 - Guided Therapeutics, Inc. today announced that it was awarded $1.0 million to fund the second year of a $2.5 million grant from the National Cancer Institute (NCI) announced in 2009.
(University of Leicester) August 20, 2010 - Dr Paul Symonds from the Department of Cancer Studies and Molecular Medicine has demonstrated that the use of a particular drug in collaboration with radiotherapy gives significantly better results than radiotherapy alone.
(Yahoo! Finance) August 18, 2010 - Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has completed the nine (9) doses to be administered to the three (3) vanguard patients in the low dose group of its phase II cervical dysplasia clinical trial study.
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies and development programs at the Canaccord Genuity 30th Annual Growth Conference .
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today reported financial results for the three months and six months ended June 30, 2010. Revenues decreased to $2.1 million for the second quarter of 2010 from $4.0 million for the second quarter of 2009, primarily as a result of a $1.5 million milestone payment in 2009 from Merck & Co., Inc., based on Merck's ongoing Phase 1 clinical-stage development of an investigational cancer vaccine.
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company will report financial results for the three months and six months ended June 30, 2010, before the opening of trading on Tuesday, August 3, and conduct a conference call and webcast to discuss the financial results and provide a company update at noon Eastern Time on Tuesday, August 3.
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that its prophylactic Vaxfectin-formulated plasmid DNA vaccine against herpes simplex virus type 2 protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites.
(Toronto Star) July 26, 2010 - A virus known to cause cervical cancer in women is increasingly being identified in head and neck cancers, leading to suspicion that the route of infection may be oral sex.
(Wall Street Journal) July 8, 2010 - Roche Holding AG Thursday said a study showed that its HPV test can detect cervical pre-cancer that could otherwise be missed in a cytologic examination.
(Yahoo! Finance) June 24, 2010 - Zetiq Technologies Ltd., a subsidiary of Bio-Light Ltd., reports the successful completion of another clinical trial to validate the effectiveness of the company's technology for early identification and diagnosis of cervical cancer, in conventional cytological smears.
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that an independent Safety Monitoring Board for the company's Phase 3 trial of Allovectin-7 in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.
(MarketWatch) June 16, 2010 - Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7(R) in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.
(Time Wellness Blog) June 14, 2010 - Though current cervical cancer screening guidelines generally recommend that women ages 30 and older get screened — either using a traditional pap smear or a complement of a pap smear and human papillomavirus testing — every 2 to 3 years instead of annually, a new survey published this week in the Archives of Internal Medicine finds that most physicians recommend screening far more frequently.
(Time Wellness Blog) June 14, 2010 - Though current cervical cancer screening guidelines generally recommend that women ages 30 and older get screened — either using a traditional pap smear or a complement of a pap smear and human papillomavirus testing — every 2 to 3 years instead of annually, a new survey published this week in the Archives of Internal Medicine finds that most physicians recommend screening far more frequently.
(TheStreet) June 8, 2010 - BSD Medical Corporation today reported significant clinical results from the use of hyperthermia to treat cervical cancer. The results were presented at the annual meeting of the European Society for Hyperthermic Oncology (ESHO), which was held in Rotterdam, The Netherlands, on May 19 to 21, 2010.
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at two upcoming investor conferences:
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will provide an overview of the company's technologies, development programs, and strategic partnerships at three upcoming investor conferences:
[GlobeNewswire] - SAN DIEGO -- Vical Incorporated announced today that the company is collaborating with leading pediatric infectious disease researchers Stuart P. Adler, M.D., and Michael A. McVoy, Ph.D., of Virginia Commonwealth University under a five-year, approximately $4.0 million grant from the National Institute of Allergy and Infectious Diseases , part of the National Institutes of Health .
[GlobeNewswire] - NEW YORK -- Vical Incorporated today announced that the company's President and Chief Executive Officer, Vijay B. Samant, will preside over The NASDAQ Stock Market Closing Bell ceremony from 3:50 p.m. to 4:05 p.m.
Dynavax shot higher on Thursday after an upgrade to Outperform from Neutral at Wedbush.
Vical Inc. reported new results from a midstage trial of its cancer drug candidate Allovectin-7 on Wednesday, and the results appeared to bode well for other studies of the treatment.